ArticleNature2024
Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Muribaculum as a microbial contributor of rifaximin-induced mucosal protection during chemotherapy.Gut microbes · 2026Article
- The gut microbiome in graft-versus-host disease: mechanisms of immune modulation and therapeutic approaches.Gut microbes · 2026Review
- The role of systemic inflammation in hepatic encephalopathy: advances in inflammatory mechanisms, prevention and treatment research.Annals of medicine · 2026Review
- Article
- Editorial: Rifaximin and the Gut-Liver-Brain Axis-Progress and Prudence.Alimentary pharmacology & therapeutics · 2026Article
- Lack of association between rifaximin and drug-resistant infections: a global multicenter inpatient cirrhosis cohort.Clinical and molecular hepatology · 2026Article
- Reducing the Risk of Overt Hepatic Encephalopathy Recurrence: A Narrative Review.Journal of clinical and translational hepatology · 2026Review
- Rifaximin's therapeutic spectrum: approved indications and experimental insights into emerging uses.Pharmacological reports : PR · 2026Review
- Single point mutations in global regulatory genes restore cephalosporin resistance in a low-MICAntimicrobial agents and chemotherapy · 2026Article
- Non-susceptibility ofMicrobiology spectrum · 2026Article
- Fecal microbiota transplantation in chronic liver disease: Current and future state of the art.Hepatology communications · 2026Review
- A Novel Use of Tenapanor in Patients With Hepatic Encephalopathy: A Case Series.ACG case reports journal · 2026Article
- BaGPipe: an automated, reproducible, and flexible pipeline for bacterial genome-wide association studies.BMC microbiology · 2026Article
- Proximity-ligation metagenomics reveals disease-specific mobilome dynamics in disrupted gut ecosystems.Research square · 2026Article
- Rising burden of enterococcal bacteremia in Victoria, Australia: population-based incidence and antimicrobial resistance trends from three decades of surveillance.Antimicrobial agents and chemotherapy · 2026Article
- Tertiary alkylamine-functionalized polyaspartamides with potent antibacterial activity.Bioactive materials · 2026Article
- Understanding Daptomycin Resistance Mechanisms and Treatment Challenges inAntibiotics (Basel, Switzerland) · 2026Article
- BeyondAntimicrobial agents and chemotherapy · 2026Article
- Disease Modulating Agents in Cirrhosis.Clinics in liver disease · 2026Review
- Antimicrobial resistance trends of ESKAPEE pathogens isolated from intensive care unit patients at a tertiary care hospital in Mogadishu, Somalia: a retrospective study (2020-2024).Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Adrianna M TurnerDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0009-0000-5840-7119
Lucy LiDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Ian R MonkDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0001-6982-8074
Jean Y H LeeDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0001-5751-8503
Danielle J IngleDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0003-0707-6537
Stephanie PortelliComputational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.ORCID 0000-0003-3515-4301
Norelle L SherryDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Nicole IslesDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Torsten SeemannDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0001-6046-610X
Liam K SharkeyDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0001-9324-8678
Calum J WalshDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Gavin E ReidSchool of Chemistry, The University of Melbourne, Melbourne, Victoria, Australia.
Shuai NieMelbourne Mass Spectrometry and Proteomics Facility, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, Victoria, Australia.
Bart A EijkelkampMolecular Sciences and Technology, College of Science and Engineering, Flinders University, Adelaide, South Australia, Australia.ORCID 0000-0003-0179-8977
Natasha E HolmesDepartment of Infectious Diseases & Immunology, Austin Health, Melbourne, Victoria, Australia.
Brennan CollisDepartment of Infectious Diseases & Immunology, Austin Health, Melbourne, Victoria, Australia.
Sara VogrinDepartment of Infectious Diseases & Immunology, Austin Health, Melbourne, Victoria, Australia.
Andreas HiergeistInstitute of Clinical Microbiology and Hygiene, University Medical Center, Regensburg, Germany.
Daniela WeberDepartment of Internal Medicine III, Hematology and Medical Oncology, University Medical Center, Regensburg, Germany.
Andre GessnerInstitute of Clinical Microbiology and Hygiene, University Medical Center, Regensburg, Germany.
Ernst HollerDepartment of Internal Medicine III, Hematology and Medical Oncology, University Medical Center, Regensburg, Germany.
David B AscherComputational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.ORCID 0000-0003-2948-2413
Sebastian DucheneDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0002-2863-0907
Nichollas E ScottDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0003-2556-8316
Timothy P StinearDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0003-0150-123X
Jason C KwongDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Claire L GorrieDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0002-2637-2529
Benjamin P HowdenDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia. bhowden@unimelb.edu.au.ORCID 0000-0003-0237-1473
Glen P CarterDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia. glen.carter@unimelb.edu.au.ORCID 0000-0002-7306-9362
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant bacterial pathogens like vancomycin-resistant Enterococcus faecium (VREfm) are a critical threat to human health
Indexed as
Anti-Bacterial AgentsAntibiotic ProphylaxisDaptomycinDrug Resistance, Multiple, BacterialEnterococcus faeciumHepatic EncephalopathyRifaximinAnimalsDNA-Directed RNA PolymerasesFemaleGram-Positive Bacterial InfectionsHumansLiver CirrhosisMiceMice, Inbred C57BLMutationAnti-Bacterial AgentsDaptomycinDNA-Directed RNA PolymerasesRifaximinVancomycin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.